The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with ...
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback